© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
In an ongoing small trial, adding a biweekly infusion of ibalizumab has helped quite a few people on failing antiretroviral regimens.
HIV-positive people 50 and older who switched from Truvada to Descovy in a recent trial reaped health benefits.
An analysis of a large patient database found that a computer algorithm could identify those at high risk for HIV.
Taking omega-3 fatty acid supplements may lower triglycerides and inflammation.
In a 111-person group of people treated for HIV, the average viral reservoir half-life was 12 years.
In a Phase III trial, participants responded well to the addition of biweekly injections of the cloned antibody ibalizumab.
It’s unclear, however, whether going on Truvada as pre-exposure prophylaxis led men who have sex with men to contract more STIs.
Just 11 percent got anal pap smears in a recent study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
